KOSDAQBiotech & Pharma001540

Ahn-Gook Pharmaceutical

₩9,950▲ 0.40%2026-11-18 close
Market Cap
₩129.8B
Turnover
₩500M
Volume
50K
Shares out.
13M
PER
4.7×
PBR
0.6×
EPS
₩2,123
Dividend Yield
6.31%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩633 per share · Prices as of the 2026-11-18 close

01

Report overview

Ahn-Gook Pharmaceutical: Cardiovascular Franchise Reshapes Earnings Mix

Ahn-Gook Pharmaceutical's cardiovascular products, led by Pevarozet, and its Health & Beauty expansion have restored profit in 2026, while quarterly earnings volatility and a temporary production halt at its Hwaseong plant remain open risks.

  1. 1

    Cardiovascular product sales reached KRW 45.0 billion in Q1 2026, up 39% year on year (Cardiovascular product sales reached KRW 450 million), and Pevarozet became the largest product at KRW 11.2 billion, or 11.3% of revenue.

  2. 2

    Annual operating profit fell to KRW 5.06 billion in 2023, then rose to KRW 6.7 billion in 2024 and KRW 9.82 billion in 2025. Cumulative operating profit for the first three quarters of 2026 reached KRW 34.6 billion, already above the full-year 2025 figure.

  3. 3

    Profit attributable to owners of the parent peaked at KRW 12.4 billion in Q1 2026 and then declined for two consecutive quarters. The sum for the last four quarters is KRW 24.1 billion.

  4. 4

    Production of tablets at the Hwaseong plant was suspended for 15 days from May 22 to June 5, 2026 under an administrative order, and tablets accounted for 68.2% of 2025 sales of the company's own-manufactured line.

  5. 5

    The 2026 corporate value-up plan lays out new product development, in-licensing of overseas drugs, expanded production capacity and process optimization as its main pillars.

02

Business structure

Ahn-Gook Pharmaceutical is a prescription-drug (ETC) company that is also building its Health & Beauty (H&B) business. Pharmaceutical segment sales were KRW 89.9 billion in Q1 2026, or 91% of total revenue.

By therapeutic class, cardiovascular product sales rose 39% year on year to KRW 45.0 billion, making it the largest category. Respiratory product sales fell 11% to KRW 15.8 billion, reducing its share from 24% to 16%.

Among individual products, the lipid-lowering combination Pevarozet became the largest product at KRW 11.2 billion, or 11.3% of sales, while Cinetura contributed KRW 8.2 billion (8.3%). H&B sales reached KRW 25.2 billion in the first three quarters of 2026, up 77.4% year on year, and accounted for 8.8% of revenue.

On an annual basis, H&B sales rose from KRW 15.6 billion in 2024 to KRW 20.8 billion in 2025. Tablets generated KRW 200 billion in 2025 sales, equal to 68.2% of standalone sales of KRW 293.3 billion.

Self-manufactured products make up more than 90% of revenue, so production efficiency and cost feed directly into profitability. On R&D, the company added CRO and drug-development advisory services to its business purpose in 2022 and launched an ophthalmology unit in 2023.

Overseas sales were KRW 0.6 billion in Q1 2026, or 0.6% of revenue, which confirms a domestically prescription-driven structure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩77.7B₩4.9B6.3%
2025Q4₩76.6B-₩5.9B−7.7%
2026Q1₩98.9B₩16B16.2%
2026Q2₩91.9B₩8.6B9.4%
2026Q3₩97.2B₩10B10.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩205.4B₩9.7B₩6.9B4.7%4.4%44.8%
2023₩233.7B₩5.1B₩1.3B2.2%0.8%57.3%
2024₩271.1B₩6.7B₩16.8B2.5%10.2%83.6%
2025₩306.9B₩9.8B₩7.5B3.2%4.5%87.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 205.4 billion in 2022 to KRW 233.7 billion in 2023 (up 13.8%), KRW 271.1 billion in 2024 (up 16.0%) and KRW 306.9 billion in 2025 (up 13.2%), and it has grown for three consecutive years from 2023 to 2025.

Operating profit fell from KRW 9.68 billion in 2022 to KRW 5.06 billion in 2023 (down 47.7%), then rose to KRW 6.7 billion in 2024 (up 32.4%) and KRW 9.82 billion in 2025 (up 46.6%), with two consecutive years of growth from 2024 to 2025.

Operating margin moved from 4.7% in 2022 to 2.2% in 2023, 2.5% in 2024 and 3.2% in 2025, a gradual recovery from the 2023 low.

Profit attributable to owners of the parent was KRW 6.88 billion in 2022, KRW 1.29 billion in 2023, KRW 16.8 billion in 2024 and KRW 7.48 billion in 2025, the largest in 2024 and down 55.6% in 2025.

Net income including non-controlling interests was KRW 16.3 billion in 2024 and KRW 7.32 billion in 2025, a different measure that should be read separately. The debt-to-equity ratio rose from 44.8% in 2022 to 87.0% in 2025, when total liabilities were KRW 144.7 billion and total equity was KRW 166.3 billion.

Operating cash flow went from KRW -1.33 billion in 2023 to KRW 4.91 billion in 2024 and KRW 45.7 billion in 2025. Quarterly, Q3 2025 revenue was KRW 77.7 billion with operating profit of KRW 4.88 billion, then Q4 2025 turned to an operating loss of KRW 5.88 billion.

Q1 2026 operating profit of KRW 16.0 billion rose 173.5% year on year, and operating margin improved from 7.7% to 16.2%. The improvement came from a gross margin of 66.8%, up 3.1 percentage points from a year earlier, while selling, general and administrative expenses rose about 21.5% to KRW 46.2 billion.

Q2 2026 operating profit was KRW 8.64 billion (down 46.1% quarter on quarter), and Q3 2026 was KRW 9.97 billion (up 15.3%), with a Q3 operating margin of 10.3%. Profit attributable to owners declined for two consecutive quarters after peaking in Q1 2026.

05

Industry analysis

The domestic pharmaceutical sector faces a difficult operating environment in 2026. The company's CEO said in the New Year address that the pharmaceutical industry is expected to face many difficulties in 2026.

On pricing, analysts note that as drug price cuts continue, lowering production costs and raising product-level cost competitiveness matters more.

In cardiovascular therapy, the company says it aims to keep expanding the share of pitavastatin-based combination drugs in a market led by rosuvastatin and atorvastatin combinations.

Analysts cite clinical results showing LDL-C improvement, with the sugar-metabolism profile of pitavastatin driving prescription growth in clinics.

In hypertension, the company received approval for Revosartan Plus tablets on April 28, 2026 and has licensed the three-drug combination Widaflic, which it expects to strengthen its position in hypertension.

Its heavy reliance on the domestic prescription market is reflected in overseas sales of just 0.6% of revenue in Q1 2026. Direct comparisons with large peers such as Yuhan and Hanmi Pharm require caution because scale and product mix differ.

In 2025 reporting, the company described its overseas expansion starting in Central America and moving into Southeast Asia and the Middle East. Product differentiation and cost control have become central variables for competitiveness within a cardiovascular-focused structure.

06

Outlook

In its 2026 corporate value-up plan, the company said it will secure differentiated products through new product development and in-licensing of overseas drugs, while strengthening cost competitiveness through capacity expansion and process optimization.

On shareholder returns, it introduced a system to set the dividend amount first and confirm the record date afterward, to improve predictability. The payout ratio for the prior fiscal year was 96.17%.

On products, the company obtained approval from the Ministry of Food and Drug Safety for a low-strength Pevarozet 1/10mg tablet, securing the lowest dose line-up.

Industry observers say that with a broader low-dose line-up and more CMO volume, annual Pevarozet sales could rise to around KRW 38.0 billion, above the internal target of KRW 35.0 billion. This is an industry estimate, and the company has not confirmed a formal guidance figure.

In its pipeline, the improved cardiovascular drug AG-1705 is in the approval process and, co-developed with Daewha Pharmaceutical, has reached the approval stage. AG-2304 is being co-developed with Boryung. Production at the Hwaseong plant resumed tablet manufacturing from June 6.

The company plans to keep R&D spending at around 5 to 6% of revenue. In a 2025 report, the company stated a medium-term goal of KRW 500 billion in annual revenue and entry into the top ten of the industry.

07

Valuation

PER
4.7×
PBR
0.6×
ROE
13.7%
EPS
₩2,123
BPS
₩16,236
Dividend per share
₩633

Price-to-book is below 1x, so the share price sits below the company's book net asset value. The price-to-earnings multiple should be read against earnings that fell in 2025 and recovered in 2026.

Profit attributable to owners over the last four quarters totals KRW 24.1 billion, which is the base for comparing the current share price with earnings. The company's prior-year payout ratio of 96.17% means most earnings went to dividends.

The company says the set-first, record-date-later system is meant to make dividends more predictable. Because the debt-to-equity ratio rose from 44.8% in 2022 to 87.0% in 2025, dividend capacity should be judged alongside cash flow and production investment needs.

Operating cash flow of KRW 45.7 billion in 2025, above the operating profit base, is a reference point for dividend sustainability. Any valuation direction will depend on quarterly earnings trends and how profitability holds after the large production investment.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Cardiovascular franchise driving growth

Cardiovascular sales reached KRW 45.0 billion in Q1 2026, up 39%, and Pevarozet became the largest product. A low-strength approval widens treatment options, and industry observers see annual Pevarozet sales possibly reaching around KRW 38.0 billion. This is an industry estimate, not company guidance.

Profitability recovery

Operating margin recovered from 2.2% in 2023 to 3.2% in 2025 and reached 16.2% in Q1 2026. Cumulative operating profit for the first three quarters of 2026 exceeded the full-year 2025 total. A higher gross margin drove most of the improvement.

Fast-growing H&B business

H&B sales reached KRW 25.2 billion in the first three quarters of 2026, up 77.4%, and made up 8.8% of revenue. That already exceeded the full-year 2025 H&B figure of KRW 20.8 billion within nine months. A second growth engine outside prescription drugs adds diversification.

09

Bear factors

Quarterly earnings volatility

Q4 2025 swung to an operating loss of KRW 5.88 billion, and Q2 2026 operating profit fell 46.1% to KRW 8.64 billion. Profit attributable to owners has declined for two quarters since the Q1 2026 peak. Given this quarterly volatility, the durability of the annual recovery has yet to be tested.

Production halt and tablet dependence

Tablet production at the Hwaseong plant was halted for 15 days under an administrative order. Tablets are central to sales, so production gaps can affect revenue directly. The company said inventory on hand allowed normal sales during the halt.

Rising costs and higher leverage

Q1 2026 SG&A rose 21.5% to KRW 46.2 billion, and advertising costs jumped 146%. The debt-to-equity ratio climbed from 44.8% in 2022 to 87.0% in 2025. Higher selling costs and rising leverage at the same time add pressure on earnings capacity.

10

Risk factors

Production and regulatory risk

Tablet production was halted for 15 days, and tablets accounted for 68.2% of 2025 sales. Whether similar administrative actions recur and how quality controls are strengthened are key points to monitor. Vulnerability to production gaps remains until the capacity expansion and process optimization are completed.

Product concentration and competition

Pevarozet alone accounts for 11.3% of Q1 2026 sales, while Cinetura's share fell from 14.5% to 8.3%. Share competition with existing combination drugs in the lipid-lowering market continues. High dependence on a few products means earnings may respond sharply to prescription shifts.

Cost and investment burden

As drug price cuts continue, product-level cost competitiveness will weigh heavily on profit. The company is carrying out large production investment, so payback timing and financial burden are variables.

Operating cash flow was KRW 45.7 billion in 2025, but investment spending and dividend policy must be managed together amid quarterly earnings swings.

11

What to watch next

  1. End of December 2026

    At fiscal year-end 2026, check whether Pevarozet annual sales approach the industry estimate of around KRW 38.0 billion. Track whether cardiovascular growth holds alongside fourth-quarter results.

  2. Late March 2027

    The 2026 annual report is the next regular filing. Check the confirmed full-year operating margin, operating cash flow and debt-to-equity ratio, and the final fourth-quarter 2026 figures.

  3. Mid-May 2027

    The Q1 2027 quarterly report is due. Check whether tablet sales recover after normalized production at Hwaseong and how the cardiovascular and H&B shares of revenue shift.

  4. First half of 2027 (timing not fixed)

    Monitor the approval progress of AG-1705 and AG-2304. Approvals would show how the cardiovascular portfolio extends beyond Pevarozet.

12

Overall view

Ahn-Gook Pharmaceutical's operating profit rose sharply in 2026, driven by Pevarozet and the expansion of its H&B business. Q1 2026 operating profit of KRW 16.0 billion marked a swing to profit, and cumulative operating profit for the first three quarters reached KRW 34.6 billion.

However, profit attributable to owners has declined for two consecutive quarters since its Q1 2026 peak, after an operating loss in Q4 2025. The 15-day production halt at the Hwaseong plant and the high revenue share of tablets remain production risks.

The debt-to-equity ratio rose from 44.8% in 2022 to 87.0% in 2025, so large investment and dividend policy must be managed together. Industry observers point to possible growth in Pevarozet sales, but this is an estimate rather than confirmed guidance.

The next checkpoints are the operating margin in the 2026 annual report and whether tablet sales recover in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. dailypharm.com
  2. medipana.com
  3. apsk.co.kr
  4. medicopharma.co.kr
  5. m.yakup.com
  6. kpanews.co.kr
  7. medicopharma.co.kr
  8. medipana.com
  9. newstomato.com
  10. m.thinkpool.com
  11. news.nate.com
  12. medigatenews.com
  13. medicaltimes.com
  14. press9.kr
  15. m.yakup.com
  16. pharmnews.com
  17. news1.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis